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Background: Several cytokines are associated with the development and/or progression of chronic heart failure
(CHF). Our aim was to look more closely at the cytokine networks involved in CHF, and to assess whether disease
etiology affects cytokine expression. The study population was comprised of a) 69 patients with stable CHF, New
York Heart Association (NYHA) II/IV classes, secondary to ischaemic (ICM) and non ischaemic dilated (NIDCM)
cardiomyopathy and b) 16 control subjects. We analyzed and compared the plasma levels of 27 pro- and anti-
inflammatory mediators, in the study population and assessed for any possible correlation with echocardiographic
parameters and disease duration.
Methods: 27 cytokines and growth factors were analyzed in the plasma of ICM- (n = 42) and NIDCM (n = 27)
NYHA class II-IV patients vs age- and gender-matched controls (n = 16) by a beadbased multiplex immunoassay.
Statistical analysis was performed by ANOVA followed by Tukey post-hoc test for multiple comparison.
Results: Macrophage inflammatory protein (MIP)-1b, Vascular endothelial growth factor (VEGF), interleukin (IL)-9,
Monocyte chemotactic protein (MCP)-1, and IL-8 plasma levels were increased in both ICM and NIDCM groups vs
controls. In contrast, IL-7, IL-5, and Interferon (IFN)-g were decreased in both ICM and NIDCM groups as compared
to controls. Plasma IL-6 and IL-1 b were increased in ICM and decreased in NIDCM, vs controls, respectively.
IL-9 levels inversely correlated, in ICM patients, with left ventricular ejection fraction (LVEF) while IL-5 plasma levels
inversely correlated with disease duration, in NYHA III/IV ICM patients.
This is the first time that both an increase of plasma IL-9, and a decrease of plasma IL-5, IL-7 and IFN-g have been
reported in ICM as well as in NIDCM groups, vs controls. Interestingly, such cytokines are part of a network of
genes whose expression levels change during chronic heart failure. The altered expression levels of MIP-1 b, VEGF,
MCP-1, IL-1 b, IL-6, and IL-8, found in this study, are in keeping with previous reports.
Conclusions: The increase of plasma IL-9, and the decrease of plasma IL-5, IL-7 and IFN-g in ICM as well as in
NIDCM groups vs controls may contribute to get further insights into the inflammatory pathways involved in CHF.
Background
The role of inflammation in the pathogenesis and pro-
gression of chronic heart failure (CHF) is well estab-
lished [1,2]. Typical hallmarks for the involvement of
immune mechanisms in CHF pathogenesis are the acti-
vation/migration of leukocytes from the circulation to
the areas of myocardial inflammation and an increased
expression of proinflammatory cytokines, such as tumor
necrosis factor a, interleukin-1, and interleukin-6 from a
damaged myocardium [3-6]. In heart failure such cyto-
kine levels increase in association with disease severity
and may contribute to impair cardiac function through
cardiomyocyte apoptosis, inflammatory response, cardiac
hypertrophy and matrix metalloproteinase activation
[1,7-9].
Proinflammatory cytokines may cause myocyte apop-
tosis and necrosis; interleukin-6 induces a hypertrophic
response in myocytes [10], whereas TNF-a causes left
ventricular dilatation, apparently through the activation
of matrix metalloproteinases [11]. Elevated levels of
CXC and C-C chemokines such as GROa, IL-8, MCP-1,
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severe cases of heart failure, which would suggest a pos-
sible role for such molecules in CHF progression
[12,13]. Peripheral blood mononuclear cells are impor-
tant players in the CHF inflammatory process [14,15].
However, the mechanisms that, in heart disease, ulti-
mately cause the transition from cardiac disease to heart
failure still need further investigation.
The identification of the cytokines associated with
chronic heart failure is not only important to get deeper
insights into the inflammatory pathways involved, but it
could also lead to the identification of disease’sb i o m a r -
kers. The biomarkers found in heart failure include
BNP, NT pro-BNP, C-reactive protein, tumor necrosis
factor a, interleukins 1 and 6, TNF-a, matrix metallo-
proteinases, neuroepinephrine, renin, galectin-3 [16-18],
some of which are also important tools in the diagnosis
and pathogenesis of heart failure, in the identification of
subjects at risk of heart failure, risk stratification, thera-
peutic agents response monitoring [17].
The aim of this study was to investigate the inflamma-
tory pathways associated with CHF, and to assess
whether disease etiology affects cytokine cascades. To
this end, we analyzed plasma cytokine levels in patients
with stable ischaemic or non ischaemic dilated cardio-
myopathy CHF vs healthy donors, by a multiplex cyto-
kine/growth factor immunoassay, and then assessed




Sixty-nine patients with chron i cs t a b l eh e a r tf a i l u r ef o r
six consecutive months were enrolled at the Cardiology
Unit of the Catholic University of Sacred Heart of Rome
out of 210 patients admitted to the unit during the
same period. Baseline patient demographic variables,
heart failure classification and echocardiographic para-
meters of patients are shown in Table 1. CHF patients
were classified in New York Heart Association (NYHA)
functional class II/IV. The causes of heart failure were
classified as 1) ICM in patients (n = 42) with a history
of myocardial infarction and coronary atherosclerosis
with a stenosis >70% in at least one major coronary
artery branch or 2) NIDCM in patients (n = 27) with no
history of myocardial infarction and angiografically nor-
mal coronary arteries. NIDCM is defined as patients
with dilated cardiomyopathy, with LVEF less than 40%,
in the absence of ischaemic or congenital heart disease,
or cardiac valve disease. LVEF and left ventricular inter-
nal diastolic diameter (LVIDd) were calculated from 2-D
and M-mode transthoracic echocardiographic images.
Duration of disease was calculated as the time between
the first ICM or NIDCM diagnosis and enrolment in
our study. Exclusion criteria were infections, malignan-
cies, autoimmune disorders, diabetes, pulmonary disease,
myocardial infarction, unstable angina or myocarditis
during the 6 months prior to enrollment in the study
and blood sample collection. Sixteen age- and sex-
matched controls were recruited at the Clinical Labora-
tory at IDI-IRCCS from randomly chosen individuals
with no overt cardiac disease and dyslipidemia. Inflam-
matory indexes, i.e. C-reactive protein (CRP) and erytro-
cyte sedimentation rate (ESR), were within physiologic
ranges and no leukocytosis was observed.
The study complies with The Helsinki Declaration and
was approved by the Ethics Committee of the Catholic
University and all subjects gave written informed
consent.
Sample collection and management
Venous blood samples (20 ml) from ICM and NIDCM
patients and controls were collected in pyrogen-free,
heparinized tubes between 8.00 am and 10.00 am and
immediately centrifuged at 3000 rpm for 15 minutes.
Plasma samples were aliquoted and stored at -80°C.
Samples were frozen and thawed only once.
Multiplex immunoassay
We used a human cytokine 27-Bio-Plex assay kit
(BioRad Laboratories, Milan, Italy), a beadbased multi-
plex immunoassay. This technology has the capacity to
measure several cytokines/cytokine receptors and
growth factors simultaneously in small volumes of
plasma or serum with a greater detection dynamic range
(~ 1-10,000 pg/mL) than single ELISAs [15-18] with
high accuracy and sensitivity [19-22].
The factors analysed were: IL1-b, IL-1 receptor
antagonist (ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9,
IL-10, IL-12, IL-15, IL-16, 1L-17, basic fibroblast growth
factor (FGF), eotaxin, granulocyte colony stimulating
Table 1 Patient characteristics
ICM (n = 42) NIDCM (n = 27)
Age mean (range) 67 ± 7.4 (47-81) 65 ± 8.7 (47-80)
Sex M/F 41/1 24/3
NYHA class II-IV II-IV
LVEF % 33 ± 8.0 28 ± 7.0




Loop diuretics 70 13
Aldosterone antagonists 34 46
Digitoxin 4 21*
Nitrate 9 3
* p < 0.05 vs ICM.
Cappuzzello et al. Journal of Translational Medicine 2011, 9:28
http://www.translational-medicine.com/content/9/1/28
Page 2 of 7factor (G-CSF), granulocyte-macrophage colony stimu-
lating factor (GM-CSF), IFN-g,I n t e r f e r o ng-inducible
p r o t e i n( I P ) - 1 0 ,M C P - 1 ,M I P - 1 a,M I P - 1b, Platelet-
derived growth factor (PDGF)-BB, Regulated on Activa-
tion Normal T-cell-Expressed and Secreted (RANTES),
Tumor necrosis factor (TNF) a and VEGF. The lower
detection limit was 0.2-19.3 pg/ml (see http://www.bio-
rad.com/webroot/web/pdf/lsr/literature/Bulletin_3157.
pdf). We tested the plasma concentrations of the above
molecules in the whole study population. The plasma
samples were diluted 1:4 and tested in duplicates. The
samples were read on a Bio-Plex 200 instrument
equipped with the software Bioplex Manager, version
4.1, using a five-parameters not-linear regression for-
mula to compute sample concentrations from the stan-
dard curves.
The pubgene program http://www.pubgene.org was
used to evaluate the expression and/or functional corre-
lation between cytokines and growth factors.
Statistical analysis
All the major study variables evaluated in the present
study were not normally distributed; thus logarithmic
transformation was applied to the data to allow para-
metric techniques to be used. The Bivariate Pearson
correlation coefficient (r) was calculated between cyto-
kine plasma levels and echocardiografic parameters or
disease duration. Statistical analysis between ICM,
NIDCM and CTRL was performed by ANOVA followed
by Tukey’s post-hoc test for multiple comparison. No
significant differences were detected in the three groups
in terms of age and gender (chi-square p value >0.05).
The cytokines and growth factor values have been
expressed as median and interquartile range and a p
value <0.05 was considered statistically significant. Pro-
portions (Table 1), were compared by Fisher’s exact test.
Results
Plasma cytokine profiles in ICM and NIDCM CHF patients
vs controls
Multiplex immunoassay screening for cytokine and
growth factor protein expression, by means of the multi-
plex XMAP technology, was performed on ICM and
NIDCM CHF patients (Table 1) and on control plasma.
The first group of factors was composed of MIP-1 b,
VEGF, MCP-1, IL-9, and IL-8, (Figure 1A-E); the levels
of these cytokines were increased in patients with ICM
as well as in NIDCM with respect to controls (p < 0.05).
Further, the IL-6 cytokine (panel F) was significantly
increased in ICM patients vs healthy controls (p < 0.05).
The cytokines and growth factor values have been
expressed as median and interquartile range.
The second group included IFN-g, IL-7, and IL-5,
whose levels were significantly lower in the plasma of
I C Ma n dN I D C Mp a t i e n t sv sh e a l t h yi n d i v i d u a l s ,s e e
Figure 2 (panel A-C). IL-1 b, on the other hand, was
only decreased in the NIDCM patients vs controls (Fig-
ure 2 panel D) (*p < 0.05).
In our study, several factors, i.e. MIP-1 b,V E G F ,
MCP-1, IL-8 and IL-6 were found to be modulated, in
CHF patients, in accordance to previous reports [9,19].
Only a few of the 27 cytokines and growth factors, i.e.
IL-2, IL-15, IL-17, bFGF, and MIP-1a showed undetect-
able levels in all three groups, except for sporadic cases.
All other detectable molecules, except the ones descri-
bedFigure 1 and 2 showed no statistically significant var-
iation between either ICM or NIDCM groups, and
controls (data not shown).
However, what was noteworthy, and described here
for the first time, was the increase of IL-9, and decrease
of IL-5, IL-7 and IFN-g plasma levels in patients with
chronic heart failure.
Using the bioinformatic analysis from the http://www.
pubgene.org program, we showed, in Figure 3 that the
molecules newly associated with chronic heart failure
(gray ovals), are linked to each other in terms of expres-
sion and/or function (black thick lines), and to a num-
ber of molecules, namely Norepinephrine, Endothelin-1,
IL-1A, Galectin-3, TNFa, IL-6 and IL-18 [13], which
play a key role in CHF (white ovals).
Correlation of cytokine plasma leves with
echocardiographic parameters and disease duration
In order to assess if our findings were clinically signifi-
cant, we correlated IL-5, IL-7, IL-9 and IFN-g plasma
levels with the patients’ echocardiographic parameters,
such as LVEF and LVIDd, and with disease duration.
Interestingly, in ICM patients, IL-9 levels inversely
correlated with left ventricular ejection fraction (LVEF)
(Table 2). Furthermore, IL-5 plasma levels inversely cor-
related with disease duration in NYHA III/IV ICM
patients (Table 2). Neither IL-7 nor IFN g instead corre-
lated with echocardiographic parameters or disease
duration, and no correlation was found between
NIDCM patients and the above mentioned parameters.
Further, no significant association was found between
modulated cytokines and LVIDd (data not shown).
Discussion
The aim of this study was to further our understanding of
the inflammatory pathways associated with CHF and to
assess whether disease etiology affects cytokine cascades.
To this end we analyzed several cytokines and growth
factors’ plasma levels with the XMAP technology. This
tecnique has previously been used in cardiovascular
research, specifically, in coronary artery disease, to evalu-
ate selected cytokine ability in predicting long-term prog-
nosis [23], and in Primary Graft Dysfunction [24].
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patterns, i.e. increased or decreased cytokine plasma
levels, in chronic heart failure (ICM and NIDCM)
patients as compared to controls. The first group was
composed of MIP-1 b,M C P - 1 ,I L - 8 ,V E G Fa n dI L - 9 ,
that were increased in both the ICM and NIDCM
patients vs controls.
The second group was composed of IL-5, IL-7, IFN-g,
which showed lower plasma levels in both the ICM and
NIDCM patients as compared to controls. Furthermore,
IL-6 increased only in ICM while IL-1 b decreased only
in NIDCM, both changes with respect to controls. Pre-
vious study results on IL-1 b systemic level changes in
heart failure have been inconsistent and reported as
either unchanged [25], increased [26], or decreased (pre-
sent study) in such patients.
Several previous reports have described the role of
cytokines and growth factors in the development and/or
progression of chronic heart failure [1,5,9,11]; further, a
number of such cytokines are regarded as disease
biomarkers [17,18]. It is worth noting that our study, for
the first time, has associated IL-5, IL-7, IL-9, and IFN-g
plasma levels with chronic heart failure.
It has been reported that IL-5 cardiac protein levels
increase four days after Myocardial Infarction (MI) in a
mouse model [27]; on the contrary, as yet no data is
available on IL-5 serum or plasma levels in chronic
heart failure patients. IL-7 is produced by stromal cells
in lymphoid tissues and is required for T cell develop-
ment and persistence in the periphery. Interestingly,
local production of IL-7 has been associated with the
maintenance and predominance of CD8+ T cells, which
cause tissue damage in human chronic Chagas’ disease
cardiomyopathy, an inflammatory-dilated cardiomyopa-
thy [28]. IL-9 is a mostly T-cell produced cytokine that
has a functional role in allergic disease and resistance to
intestinal nematodes [29], but no data is yet available on
its role in heart disease. IFN-g is an important pro-
inflammatory cytokine produced by Th1 cells, that

























































































































C ICM NIDCM C ICM NIDCM C ICM NIDCM
0
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Figure 1 Cytokine plasma levels increased in ICM and NIDCM CHF patients vs controls. Plasma levels of MIP-1 b (A), VEGF (B), MCP-1 (C),
IL-9 (D), IL-8 (E), and IL-6 (F) in patients with chronic heart failure (ICM n = 42; NIDCM n = 27) classified in NYHA class II-IV and in 16 healthy
controls. Data are shown as “box-and-whiskers” plots (medians, 25
th to 75
th percentiles. * p < 0.05 vs controls.
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tive CD4 (+) T cells, has previously been described in
patients with CHF [30]. Furthermore, an increase in IFN
g serum levels has also been described [31], in a mouse
model, one week after MI, i.e. not in chronic heart fail-
ure experimental conditions.
Our study recorded decreased IL-5 plasma levels in
both ICM and NIDCM groups vs controls. Interestingly,
IL-5 plasma levels inversely correlated with disease
duration in NYHA III/IV ICM patients. In fact, patients
with longer disease duration had smaller concentrations
of plasmatic IL-5 in comparison with patients more
recently diagnosed. Furthermore, a statistically signifi-
cant correlation with IL-5 plasma levels was found only
among NYHA III/IV ICM patients, but not among
patients with less severe chronic heart failure. This
would suggest that decreased levels of this cytokine are
associated with disease progression.
We here showed an increase in IL-9 levels in both
I C Ma n dN I D C Mg r o u p sv sc o n t r o l sa n dt h a tI L - 9
levels inversely correlated with ejection fraction in ICM
patients, but not in NIDCM patients. This would sug-
gest that increased levels of this cytokine are associated
with left ventricular dysfunction and, thus, with disease
progression toward organ failure in ICM patients.
Further, we reported a decrease in plasma IFN-g levels
and of IL-7 in both ICM and NIDCM CHF patients vs
controls, but no correlation with echocardiographic
parameters or duration of disease was found (not
shown).
Nevertheless, our conclusions cannot broadly apply to



















































































C ICM NIDCM C ICM NIDCM
Figure 2 Cytokine plasma levels decreased in ICM and NIDCM CHF patients vs controls. Plasma levels of IFN-g (A), IL-7 (B), IL-5 (C) and IL-1
b (D) in patients with chronic heart failure (ICM n = 42; NIDCM n = 27) classified in NYHA class II/IV and in 16 healthy controls. Data are given as
medians and 25
th to 75
th percentile. * p < 0.05 vs controls.
Cappuzzello et al. Journal of Translational Medicine 2011, 9:28
http://www.translational-medicine.com/content/9/1/28
Page 5 of 7small number of women were enrolled and analysed in
both the ICM and NIDCM groups.
Interestingly, the cytokines that were identified in the
present study are part of a gene network of expression/
function regulation that link them to Norepinephrine,
Endothelin-1, IL-1A, Galectin-3, TNFa,I L - 6a n dI L - 1 8
[13], which are molecules associated with chronic heart
failure [1,4,7,10,11,17,18]; thus we hypothesize that IL-5,
IL-7, IL-9 and IFN-g are part of signaling cascades that
contribute to the development and/or progression of
chronic heart failure.
Notwithstanding the ICM and NIDCM difference in
pathogenetic causes there was a similar cytokine expres-
sion pattern when compared to controls. In fact, among
all cytokines previously reported as being associated
with CHF, our study showed only IL-6 and IL-1 b modi-
fication to be associated uniquely with ICM or NIDCM,
respectively. All the other cytokines instead similarly
increased or decreased, vs controls, regardless of the
etiology. Further, we found that IL-1Ra was able to dis-
criminate between the two patient groups, since it was
statistically higher in the ICM group, although only a
small increase was observed (data not shown).
In conclusion, the novelty in our study results is the
increase of IL-9 and decrease of IL-5, IL-7, and IFN-g
plasma levels, in both ICM and NIDCM CHF patients
vs controls and the inverse correlation of IL-5 and IL-9
plasma levels with duration of disease and LVEF, respec-
tively, in ICM patients. Further studies are needed to












Figure 3 Gene networks in CHF. The lines link genes whose expression or function is affected by neighbouring genes. The gene network has
been generated using the PUBGENE program http://www.pubgene.org. White ovals: genes previously known to be modulated in CHF. Grey
ovals: genes found to be regulated in CHF in the present study. Endothelin-1 (ET-1), Galectin 3 (GAL3), Norepinephrine (NOR), Tumor necrosis
factor (TNF) a, Interferon (IFN)- g, Interleukin (IL) 1A, 5, 6, 7, 9, 18.
Table 2 Correlation between cytokine plasma levels and
duration of disease or ejection fraction
Cytokine IL-5 IL-9
Duration of disease r = -0.475 (p = 0.05) n.s.
Left Ventricular Ejection
Fraction
n.s. r = -0.364 (p = 0.02)
A negative Pearson’s correlation coefficient (r) indicates that cytokine
expression inversely correlates with the variable in exam (e.g. : patients with
longer disease duration had smaller concentrations of plasmatic IL-5 in
comparison with patients more recently diagnosed).
A statistically significant inverse correlation of IL-9 plasma levels with left
ventricular ejection fraction was found among the ICM group only (n = 42).
An inverse correlation between IL-5 plasma levels and duration of disease was
found in NYHA III-IV ICM patients only (n = 18).
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Page 6 of 7IFN-g plasma levels has a null, a protective, or a patho-
genetic role in chronic heart failure and may constitute
a potential target for therapeutic intervention.
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